Pediatric use of antihypertensive medications: Much more to learn

Current Therapeutic Research - Clinical and Experimental

Volumn 62, Issue 4, 2001, Pages 314-328

  Flynn, Joseph T ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Children; Clinical trials; Drug therapy; Hypertension; US Food and Drug Administration Modernization Act

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; FOSINOPRIL; HYDROCHLOROTHIAZIDE; ISRADIPINE; LISINOPRIL; METOPROLOL; NIFEDIPINE; PROPRANOLOL; QUINAPRIL; VERAPAMIL;

ACUTE KIDNEY FAILURE; ANOREXIA; ASTHMA; BRADYCARDIA; CARDIOMYOPATHY; CHILD; CONFERENCE PAPER; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG USE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOTENSION; INCIDENCE; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; TACHYCARDIA;

EID: 0035021702     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(01)80015-1     Document Type: Conference Paper

References (86)

1. Pharmacological management of hypertension in paediatric patients: A comprehensive review of the efficacy, safety and dosage guidelines of the available agents
2. Application since 1980 of anti-hypertensive agents to treat pediatric disease
3. Hypertension in pediatric patients
4. Report of the second task force on blood pressure control in children - 1987
5. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: A working group report from the National High Blood Pressure Education Program
6. Pediatric hypertension: Clinical perspective
7. Hypertension in children
8. Hypertension in childhood and adolescence
9. Persistent elevation of blood pressure among children with a family history of hypertension: The Minneapolis Children's Blood Pressure Study
10. Prevalence of "significant" hypertension in junior high school-aged children: The Children and Adolescent Blood Pressure Program
11. Essential hypertension in childhood and adolescence
12. Secular trends of blood pressure and body size in a multi-ethnic adolescent population: 1986 to 1996
13. Management of hypertension in the child with chronic renal disease
14. Safety and effectiveness data: Will children gain access?
15. Trials of antihypertensive therapies in children
16. Treatment of hypertension in children
17. Efficacy of captopril in the treatment of severe childhood hypertension: Report of the International Collaborative Study Group
18. Antihypertensive drug therapy with captopril in children and adolescents
19. Treatment of neonatal hypertension with captopril
20. Long-term treatment with captopril in pediatric patients with severe hypertension and chronic renal failure
21. Treatment of renal hypertension in children by captopril
22. Renal failure in sick hypertensive premature infants receiving captopril therapy
23. Pediatric use chart review study
24. Ocena skutecznosci 1 bezpieczenstwa monoteparii znamiennego nadcisnienia tetniczego u mlodziezy pryz zastosowaniu enalaprylu
25. Enalapril: A well-tolerated and efficacious agent for the pediatric hypertensive patient
26. Effects of the ACE inhibitor, enalapril, in children age 6-16 years with hypertension
27. Multicenter study of enalapril pharmacokinetics in hypertensive children and infants
28. Relative bioavailability of an enalapril suspension for oral administration to children compared to VASOTEC™ tablets
29. Medical management of hypertension in childhood
30. Propranolol as an antihypertensive agent in children
31. Propranolol versus chlorthalidone - A prospective therapeutic trial in children with chronic hypertension
32. Oral propranolol treatment in infants and children
33. Sodium nitroprusside and propranolol therapy for management of postcoarctectomy hypertension
34. High-dose propranolol therapy in the management of supraventricular tachycardia
35. Therapeutic effect of propranolol on paradoxical hypertension after repair of coarctation of the aorta
36. Beta-blocker therapy of severe congestive heart failure in infants with left to right shunts
37. A cohort study of childhood hypertrophic cardiomyopathy: Improved survival following high-dose beta adrenoceptor antagonist treatment
38. Propranolol therapy for portal hypertension in children
39. Propranolol in prevention of portal hypertensive hemorrhage in children: A pilot study
40. Successful treatment of supraventricular tachycardia with metoprolol, a cardioselective beta blocker
41. Beta-blocker therapy in young children with congestive heart failure under consideration for heart transplantation
42. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: A multi-institutional experience
43. Atenolol in children with supraventricular tachycardia
44. Long-term efficacy and safety of atenolol for supraventricular tachycardia in children
45. Randomized comparison of atenolol and fludrocortisone acetate in the treatment of pediatric neurally mediated syncope
46. Atenolol therapy for exercise-induced hypertension after aortic coarctation repair
47. Pharmacokinetics and pharmacodynamics of atenolol in children
48. A double-blind comparison of bisoprolol and atenolol in patients with essential hypertension
49. Bisoprolol, a once-a-day beta-blocking agent for patients with mild to moderate hypertension
50. Low-dose bisoprolol/hydrochlorothiazide: An option in first-line, antihypertensive treatment
51. A double-blind, placebo-controlled, dose escalation safety and efficacy study of Ziac® in patients ages 6-17 years with hypertension
52. Hemodynamic effects of verapamil in children and adolescents with hypertrophic cardiomyopathy
53. Verapamil therapy in infants with hypertrophic cardiomyopathy
54. Verapamil: An effective calcium channel blocking agent for pediatric patients
55. Cardiac arrhythmias in childhood. Diagnostic considerations and treatment
56. Safety, tolerability, and pharmacokinetic actions of diltiazem in pediatric liver transplant recipients on cyclosporine
57. Diltiazem reduces pulmonary arterial pressures in recurrent pulmonary hypertension associated with pulmonary hypoplasia
58. Effect of chronic treatment with the calcium antagonist diltiazem in Duchenne muscular dystrophy
59. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis
60. Nifedipine in hypertensive emergencies of children
61. Nifedipine in hypertensive crises of infants and children
62. Effect of sublingual or oral nifedipine in the treatment of hypertension
63. Sublingual nifedipine in acute severe hypertension
64. Oral nifedipine in the treatment of hypertensive urgency: Cerebrovascular accident following a single dose
65. Adverse neurologic events associated with nifedipine use in childhood hypertension
66. A crossover comparison of extended release felodipine with prolonged action nifedipine in hypertension
67. Use of calcium-channel blockers in pediatric renal transplant recipients
68. Efficacy of isradipine as an antihypertensive agent in children
69. Stability of isradipine in an extemporaneously compounded oral liquid
70. The pharmacokinetics of extended release felodipine in children
71. Amlodipine: A new calcium antagonist
72. Efficacy of amlodipine in pediatric bone marrow transplant patients
73. Amlodipine once-daily in systemic hypertension
74. Efficacy of amlodipine in pediatric patients with hypertension
75. Treatment of hypertensive children with amlodipine
76. The safety and efficacy of the calcium channel blocker (CCB) amlodipine in the treatment of secondary hypertension in children
77. Stability of amlodipine besylate in two liquid dosage forms
78. Clinical response of hypertensive children to long-term minoxidil therapy
79. Severe hypertension in children with renal disease: Treatment with minoxidil
80. Minoxidil for control of acute blood pressure elevation in chronically hypertensive children
81. The pharmacology and therapeutics of diuretics in the pediatric patient
82. Lack of pediatric drug formulations
83. Stability of hydralazine hydrochloride syrup compounded from tablets